GR
GRDN.US Guardian Pharmacy Services, Inc.
- Market cap
- USD 3.14B
- P/E
- 42.3x
- P/B
- 11.71x
- ROE
- 26.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GRDN.US undervalued?
Graham numberThe Graham number of Guardian Pharmacy Services, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guardian Pharmacy Services, Inc. fundamental analysis
No fundamental analysis for Guardian Pharmacy Services, Inc. yet.
Guardian Pharmacy Services, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created u…
Full company profileGuardian Pharmacy Services, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guardian Pharmacy Services, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 600M | 698M | 736M | 792M | 909M | 1.05B | 1.23B | 1.45B | 1.41B |
| Gross Profit | 123M | 143M | 147M | 161M | 186M | 208M | 244M | 282M | 322M |
| Operating Income | 25.9M | 34.1M | 32.1M | 30.2M | 52.0M | 40.9M | -62.9M | 88.9M | 84.5M |
| EBITDA | 38.3M | 49.5M | 49.1M | 46.5M | 68.2M | 58.8M | -43.4M | 96.4M | 123M |
| Net Income | 14.7M | 21.7M | 19.9M | 16.3M | 35.4M | 23.9M | -87.3M | 49.2M | 71.8M |
| EPS | 0.24 | 0.36 | 0.33 | 0.27 | 0.58 | 0.39 | -1.41 | 0.78 | 1.12 |
| Balance Sheet | |||||||||
| Total Assets | 182M | 197M | 218M | 236M | 256M | 271M | 321M | 413M | 492M |
| Total Liabilities | 114M | 139M | 151M | 183M | 180M | 211M | 171M | 195M | 212M |
| Shareholders' Equity | 34.0M | 57.0M | 38.5M | 23.9M | 42.7M | 28.2M | 143M | 206M | 267M |
| Cash & Short-term Investments | 2.25M | 275K | 6.45M | 15.0M | 607K | 752K | 4.66M | 65.6M | 120M |
| Total Debt | 43.7M | 57.1M | 58.8M | 55.0M | 63.0M | 69.2M | 30.1M | 37.1M | 35.6M |
| Cash Flow | |||||||||
| Operating Cash Flow | 43.7M | 56.2M | 52.6M | 58.5M | 48.5M | 70.8M | 58.0M | 100M | 106M |
| Capital Expenditure | 10.0M | 14.5M | 8.34M | 9.28M | 16.8M | 14.6M | 16.4M | 19.6M | 18.2M |
| Free Cash Flow | 33.7M | 41.6M | 44.3M | 49.2M | 31.8M | 56.3M | 41.6M | 80.7M | 87.7M |
| Ratios | |||||||||
| ROE | 43.1% | 38.1% | 51.8% | 68.2% | 82.9% | 84.7% | -61.2% | 23.9% | 26.9% |
| ROA | 8.1% | 11.1% | 9.2% | 6.9% | 13.8% | 8.8% | -27.2% | 11.9% | 14.6% |
| Net Profit Margin | 2.4% | 3.1% | 2.7% | 2.1% | 3.9% | 2.3% | -7.1% | 3.4% | 5.1% |
| Debt to Equity | 1.28x | 1.00x | 1.53x | 2.30x | 1.47x | 2.45x | 0.21x | 0.18x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guardian Pharmacy Services, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 35.8M | 0.58 | - |
| 2023 | USD 38.4M | 0.63 | 160.7% |
| 2022 | USD 30.8M | 0.51 | 87.0% |
| 2021 | USD 17.4M | 0.29 | 106.4% |
| 2020 | USD 10.8M | 0.18 | 54.2% |
| 2019 | USD 34.3M | 0.56 | 157.8% |
| 2018 | USD 28.0M | 0.46 | 190.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Guardian Pharmacy Services, Inc.
- Insiders 45.18%
- Institutions 47.61%
- Public & others 7.21%
- Shares outstanding 63.3M
- Free float 35.9M
Top funds holding GRDN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.03M | 1.62% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 805K | 1.27% | 0.00% | Oct 2026 |
| Loomis Sayles Small Cap Growth Instl | 604K | 0.95% | +21.02% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 571K | 0.90% | +6.04% | Aug 2026 |
| Fidelity Small Cap Growth | 477K | 0.75% | 0.00% | Aug 2026 |
| Putnam Core Equity Fund Y | 447K | 0.71% | -10.92% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 339K | 0.53% | -0.57% | Sep 2026 |
| T. Rowe Price US Smlr Coms Eq A | 335K | 0.53% | 0.00% | Sep 2026 |
| Fidelity Small Cap Stock | 311K | 0.49% | +25.05% | Aug 2026 |
| First Trust US Equity Opportunities ETF | 300K | 0.47% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 299K | 0.47% | -0.38% | Oct 2026 |
| Fidelity Series Small Cap Opps | 288K | 0.45% | -6.83% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 242K | 0.38% | 0.00% | Aug 2026 |
| Templeton Global Smaller Comp Fund A | 233K | 0.37% | 0.00% | Sep 2026 |
| AST Small-Cap Equity Portfolio | 218K | 0.34% | -3.93% | Sep 2026 |
| Fidelity Select Health Care Svcs Port | 213K | 0.34% | -3.83% | Sep 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 201K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 198K | 0.31% | 0.00% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 196K | 0.31% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 189K | 0.30% | +154.99% | Sep 2026 |
Top institutions holding GRDN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 3.24M | 5.12% | +37.39% | Jun 2026 |
| Wellington Management Company LLP | 1.73M | 2.73% | -2.04% | Jun 2026 |
| BlackRock Inc | 1.58M | 2.49% | -10.27% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.38M | 2.18% | +12.58% | Jun 2026 |
| Woodline Partners LP | 1.31M | 2.06% | +0.00% | Jun 2026 |
| Valiant Capital Management LP | 1.19M | 1.87% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.12M | 1.76% | +8.60% | Jun 2026 |
| Boston Partners Global Investors, Inc | 984K | 1.55% | -3.32% | Jun 2026 |
| Franklin Templeton Inc | 966K | 1.53% | +1.39% | Jun 2026 |
| Loomis, Sayles & Company LP | 870K | 1.37% | -6.64% | Jun 2026 |
| TimesSquare Capital Management, LLC | 777K | 1.23% | -18.31% | Sep 2026 |
| BOONE CAPITAL MANAGEMENT LLC | 712K | 1.12% | +12.79% | Jun 2026 |
| Geode Capital Management, LLC | 647K | 1.02% | +15.68% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 641K | 1.01% | +24.21% | Sep 2026 |
| Jennison Associates LLC | 627K | 0.99% | -23.84% | Jun 2026 |
| State Street Corp | 590K | 0.93% | +15.93% | Jun 2026 |
| Bessemer Group Inc | 548K | 0.87% | +596.74% | Jun 2026 |
| Brown Advisory Holdings Inc | 524K | 0.83% | -58.38% | Jun 2026 |
| Driehaus Capital Management LLC | 510K | 0.81% | -13.40% | Jun 2026 |
| First Trust Advisors L.P. | 461K | 0.73% | +392.44% | Jun 2026 |
Guardian Pharmacy Services, Inc. company profile
- Company name
- Guardian Pharmacy Services, Inc.
- Ticker
- GRDN.US
- Exchange
- USA Stocks
- Listed since
- Sep 26, 2024
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 3,600
- Fiscal year end
- December
- Address
- 300 Galleria Parkway SE, Atlanta, GA, United States, 30339
- Phone
- 404 810 0089
- Website
- guardianpharmacy.com
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
Guardian Pharmacy Services, Inc. management
10- Mr. Fred P. BurkeCEO, President & Director · born 1950
- Mr. David K. MorrisCOO & Director · born 1964
- Mr. Will Mudd CPASenior VP & CFO · born 1979
- Mr. David MartinSenior VP of Technology, Data & Senior Security Officer
- Ms. Ashley StocktonHead of Investor Relations & Senior Director
- Mr. Douglas TownsSenior VP, General Counsel, Senior Compliance Officer & Corporate Secretary
- Ms. Vicki CrabtreeVice President of Human Resources
- Mr. Jeff Tuch CPASVP of Purchasing & Pricing Analytics
- Bob Weir R.PhSVP of Operations & Regulatory Support
- Mr. Rockford AndersonPresident of Right Dose Pharmacy - Iowa